Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Receives Average Rating of “Buy” from Brokerages

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) has been given an average rating of “Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $12.67.

A number of analysts recently weighed in on the stock. Wells Fargo & Co reaffirmed a “buy” rating on shares of Osmotica Pharmaceuticals in a report on Friday, August 9th. Jefferies Financial Group set a $10.00 price objective on shares of Osmotica Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 12th. ValuEngine cut shares of Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Finally, Zacks Investment Research cut shares of Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, September 7th.

OSMT stock opened at $4.00 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.78 and a debt-to-equity ratio of 1.05. Osmotica Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $9.75. The firm’s 50-day simple moving average is $4.14 and its 200 day simple moving average is $3.47. The stock has a market cap of $207.63 million and a PE ratio of -7.84.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.06. Osmotica Pharmaceuticals had a negative net margin of 97.91% and a negative return on equity of 32.14%. The business had revenue of $57.53 million for the quarter, compared to analysts’ expectations of $57.90 million. Equities analysts forecast that Osmotica Pharmaceuticals will post -0.98 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in OSMT. Northern Trust Corp grew its position in Osmotica Pharmaceuticals by 5.6% in the 2nd quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock valued at $378,000 after buying an additional 5,230 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Osmotica Pharmaceuticals by 1,412.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 9,454 shares of the company’s stock valued at $36,000 after buying an additional 8,829 shares in the last quarter. First Trust Advisors LP bought a new position in Osmotica Pharmaceuticals in the 3rd quarter valued at about $69,000. Citadel Advisors LLC bought a new position in Osmotica Pharmaceuticals in the 2nd quarter valued at about $120,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in Osmotica Pharmaceuticals in the 2nd quarter valued at about $142,000. 6.94% of the stock is currently owned by institutional investors and hedge funds.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Read More: Buy-Side Analysts

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.